| 前收市價 | 6.80 |
| 開市 | 6.90 |
| 買盤 | 8.60 |
| 賣出價 | 9.70 |
| 拍板 | 17.50 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 6.80 - 6.90 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 130 |
ZacksIntra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BenzingaWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint. The company plans to provide an update on the
Insider MonkeyEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePoint Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Kevin and I will be your conference operator today. At this time, […]
